Peter Soukas is a Cardiology physician affiliated with Brown University. OpenAlex indexes 112 publications with 3,494 citations (h-index 23); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- In-Stent Restenosis Post-Approval Study
Sponsor: W.L.Gore & Associates
- Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy
Sponsor: Boston Scientific Corporation
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
65 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
65 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
66%Beta blocker18.5%Metoprolol Tartrate51%Metoprolol Succinate43%Carvedilol7%Part D<11 patientsStatin17.4%Atorvastatin Calcium72%Rosuvastatin Calcium17%Pravastatin Sodium11%Part D<11 patients+ 11 more classes in this area
Blood & clotting
30.1%P2Y12 inhibitor17.4%Clopidogrel68%Prasugrel Hcl20%Brilinta12%Part D<11 patientsFactor Xa inhibitor8.6%Eliquis73%Xarelto27%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
1.9%SGLT2 inhibitor0.9%Jardiance100%Part D<11 patientsPotassium supplement0.9%Klor-Con M20100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Josiah Rich, MD
Brown University
Audrey Tyrka, MD, PhD
Brown University
Edward Huey, MD
Brown University
Richard Millman, MD
Brown University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”